Literature DB >> 26841013

Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.

Anna Alperovich1, Anas Younes.   

Abstract

The expression of CD30 receptors is one of the defining characteristics of the malignant Reed-Sternberg cells of Hodgkin lymphoma (HL). CD30 is rarely expressed by normal cells and is rapidly internalized, making it an ideal therapeutic target for monoclonal antibodies and for antibody-drug conjugates. Brentuximab vedotin is the first antibody-drug conjugate to be approved by regulatory agencies for the treatment of patients with relapsed HL, with a single-agent response rate of 75%. In this review article, we discuss the current and ongoing development of brentuximab vedotin in patients with relapsed and newly diagnosed HL.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26841013      PMCID： PMC5042201          DOI： 10.1097/PPO.0000000000000168

Source DB:  PubMed          Journal:  Cancer J        ISSN： 1528-9117            Impact factor:   3.360


  9 in total

1.  Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

Authors:  Anas Younes; Nancy L Bartlett; John P Leonard; Dana A Kennedy; Carmel M Lynch; Eric L Sievers; Andres Forero-Torres
Journal:  N Engl J Med       Date:  2010-11-04       Impact factor: 91.245

2.  Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma.

Authors:  Anne-Sophie Michallet; Yann Guillermin; Benedicte Deau; Laure Lebras; Stephanie Harel; Sandy Amorin; Claire Reynes; Gilles Salles; Fabien Subtil; Pauline Brice
Journal:  Haematologica       Date:  2015-04-03       Impact factor: 9.941

3.  Brentuximab Vedotin in Combination With Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study.

Authors: 
Journal:  Clin Adv Hematol Oncol       Date:  2016-02

4.  PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.

Authors:  Alison J Moskowitz; Heiko Schöder; Joachim Yahalom; Susan J McCall; Stephanie Y Fox; John Gerecitano; Ravinder Grewal; Paul A Hamlin; Steven Horwitz; Rachel Kobos; Anita Kumar; Matthew Matasar; Ariela Noy; M Lia Palomba; Miguel-Angel Perales; Carol S Portlock; Craig Sauter; Neerav Shukla; Peter Steinherz; David Straus; Tanya Trippett; Anas Younes; Andrew Zelenetz; Craig H Moskowitz
Journal:  Lancet Oncol       Date:  2015-02-13       Impact factor: 41.316

Review 5.  CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy.

Authors:  B Falini; S Pileri; G Pizzolo; H Dürkop; L Flenghi; F Stirpe; M F Martelli; H Stein
Journal:  Blood       Date:  1995-01-01       Impact factor: 22.113

6.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Authors:  Anas Younes; Ajay K Gopal; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Radhakrishnan Ramchandren; Nancy L Bartlett; Bruce D Cheson; Sven de Vos; Andres Forero-Torres; Craig H Moskowitz; Joseph M Connors; Andreas Engert; Emily K Larsen; Dana A Kennedy; Eric L Sievers; Robert Chen
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

7.  Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Craig H Moskowitz; Auayporn Nademanee; Tamas Masszi; Edward Agura; Jerzy Holowiecki; Muneer H Abidi; Andy I Chen; Patrick Stiff; Alessandro M Gianni; Angelo Carella; Dzhelil Osmanov; Veronika Bachanova; John Sweetenham; Anna Sureda; Dirk Huebner; Eric L Sievers; Andy Chi; Emily K Larsen; Naomi N Hunder; Jan Walewski
Journal:  Lancet       Date:  2015-03-19       Impact factor: 79.321

8.  Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation.

Authors:  Ajay K Gopal; Radhakrishnan Ramchandren; Owen A O'Connor; Robert B Berryman; Ranjana H Advani; Robert Chen; Scott E Smith; Maureen Cooper; Achim Rothe; Jeffrey V Matous; Laurie E Grove; Jasmine Zain
Journal:  Blood       Date:  2012-04-17       Impact factor: 22.113

9.  Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.

Authors:  Anas Younes; Joseph M Connors; Steven I Park; Michelle Fanale; Megan M O'Meara; Naomi N Hunder; Dirk Huebner; Stephen M Ansell
Journal:  Lancet Oncol       Date:  2013-11-15       Impact factor: 41.316
  9 in total
  12 in total

1.  Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma.

Authors:  Paul G Rubinstein; Page C Moore; Michelle A Rudek; David H Henry; Juan C Ramos; Lee Ratner; Erin Reid; Elad Sharon; Ariela Noy
Journal:  AIDS       Date:  2018-03-13       Impact factor: 4.177

Review 2.  Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?

Authors:  Niloufer Khan; Alison J Moskowitz
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

3.  Targeting the seeds of small cell lung cancer.

Authors:  Sylvia Mahara; Ron Firestein
Journal:  Ann Transl Med       Date:  2017-03

4.  [Relapsed Hodgkin lymphoma with only breast involvement: a rare case report].

Authors:  Najat Lasri; Fatimazahra Lahlimi; Mohammed Ilias Tazi
Journal:  Pan Afr Med J       Date:  2022-05-12

5.  Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working Group.

Authors:  Lia Gore; S Percy Ivy; Frank M Balis; Eric Rubin; Katherine Thornton; Martha Donoghue; Samantha Roberts; Suanna Bruinooge; Jennifer Ersek; Nancy Goodman; Caroline Schenkel; Gregory Reaman
Journal:  J Clin Oncol       Date:  2017-10-02       Impact factor: 44.544

6.  Identification of key genes and pathways associated with classical Hodgkin lymphoma by bioinformatics analysis.

Authors:  Zhixing Kuang; Li Guo; Xun Li
Journal:  Mol Med Rep       Date:  2017-08-03       Impact factor: 2.952

7.  Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma.

Authors:  Dai Maruyama; Kiyohiko Hatake; Tomohiro Kinoshita; Noriko Fukuhara; Ilseung Choi; Masafumi Taniwaki; Kiyoshi Ando; Yasuhito Terui; Yusuke Higuchi; Yasushi Onishi; Yasunobu Abe; Tsutomu Kobayashi; Yukari Shirasugi; Kensei Tobinai
Journal:  Cancer Sci       Date:  2017-05-19       Impact factor: 6.716

8.  Population Pharmacokinetic Modeling and Exposure-Response Assessment for the Antibody-Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON-1 Study.

Authors:  Ajit Suri; Diane R Mould; Gregory Song; Graham P Collins; Christopher J Endres; Jesús Gomez-Navarro; Karthik Venkatakrishnan
Journal:  Clin Pharmacol Ther       Date:  2019-07-09       Impact factor: 6.875

9.  Population PK and Exposure-Response Relationships for the Antibody-Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study.

Authors:  Ajit Suri; Diane R Mould; Yi Liu; Graham Jang; Karthik Venkatakrishnan
Journal:  Clin Pharmacol Ther       Date:  2018-02-23       Impact factor: 6.875

10.  Hodgkin Lymphoma Mimicking Inflammatory Breast Carcinoma: A Rare Case with Diagnostic Challenge and Novel Treatment.

Authors:  Eleni Thodou; Maria Befani; George Triantafyllidis; Theodosia Choreftaki; George Kanellis; Nikolaos Giannakoulas
Journal:  Case Rep Hematol       Date:  2019-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.